|
|
|
|
|
|
|
|
Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells
Highlights
►
Navitoclax and other BH3 mimetics have previously shown synergy with
chemotherapeutic agents
► Where antagonism between carboplatin and/or paclitaxel was observed, this was reduced by the inclusion of navitoclax.
► Navitoclax improves the activity of carboplatin and/or paclitaxel in Igrov-1 spheroids.
► Where antagonism between carboplatin and/or paclitaxel was observed, this was reduced by the inclusion of navitoclax.
► Navitoclax improves the activity of carboplatin and/or paclitaxel in Igrov-1 spheroids.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.